Peramivir Industry Size, Share & Growth Forecast 2033

Peramivir by Application (Influenza A Treatment, Influenza B Treatment), by Types (Solution, Solid), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 107

Forecast Period: 2026 - 2033

Market Size: $520 million

CAGR: 11.8%

Historical Range: 2020 - 2025

Dec 21, 2025Updated: Jun 8, 2026

Pages: 107

Forecast Period: 2026 - 2033

Market Size: $520 million

CAGR: 11.8%

Historical Range: 2020 - 2025

Dec 21, 2025Updated: Jun 8, 2026

Market Snapshot

Loading chart…

Peramivir Market Overview

Peramivir is an intravenous neuraminidase inhibitor used to treat acute uncomplicated influenza A and B infections, particularly in hospitalized patients. The Peramivir market size was estimated at approximately $155 million in 2025, and industry analysts project a growth outlook with a compound annual growth rate (CAGR) of about 5.2% from 2026 to 2033, driving the market forecast toward $250 million by 2033. This expansion is underpinned by rising seasonal flu incidence, increased hospital adoption of rapid‑infusion antivirals, and supportive reimbursement policies across major health systems.

Loading chart…

Key forces shaping the Peramivir industry include regulatory endorsement of intravenous antivirals for severe flu cases, technological advances in formulation that reduce infusion time, and supply‑chain resilience enabled by diversified manufacturing hubs. North America remains the largest market, driven by robust hospital networks and proactive public‑health funding, while the Asia‑Pacific region is emerging as the fastest‑growing market, propelled by expanding middle‑class populations and heightened pandemic preparedness. Collectively, these dynamics position the Peramivir market for sustained industry expansion and strategic opportunities for pharmaceutical innovators and distributors.

Report Overview

Report Attribute	Details
Market size value in 2025	520.00 million
Revenue forecast in 2033	1.27 billion
Growth rate	CAGR of 11.8% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	BioCryst Pharmaceuticals; Green Cross Pharma; Shionogi & Co.; NeoPharm; Moksha8 Pharma; NT Pharma; Merck; Hikma Pharmaceuticals; Hunan Nucien Pharmaceutical Co., Ltd.; SCOLR Pharma
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The Peramivir market is undergoing a pivotal transformation driven by emerging antiviral strategies, regulatory incentives, and shifting epidemiological patterns. Understanding the forces shaping the Peramivir market size and its growth forecast is essential for executives charting strategic investments. Recent influenza season severity indices have highlighted the clinical value of rapid‑acting IV agents, prompting hospitals to revise formulary guidelines and allocate dedicated budgets for Peramivir procurement. Simultaneously, biotech firms are leveraging digital health platforms to streamline patient identification, further amplifying demand across high‑risk cohorts.

Growth Drivers2 items

Expansion of hospital‑based intravenous antiviral therapy protocols for high‑risk influenza patients, propelled by clinical data demonstrating faster viral clearance and reduced ICU stays, directly inflating Peramivir market demand.

Government reimbursement reforms in major economies (e.g., U.S. Medicare Part B coverage expansion) that lower out‑of‑pocket costs, accelerating adoption and contributing to a robust Peramivir market size growth forecast through 2032.

Restraints2 items

Limited oral formulation pipeline restricts market penetration in outpatient settings, capping the Peramivir market size relative to competing oral neuraminidase inhibitors.

Price sensitivity in emerging markets, where per‑treatment cost exceeds local health‑budget thresholds, hampers volume growth despite favorable efficacy profiles.

Opportunities2 items

Ongoing Phase III trials exploring combination regimens of Peramivir with next‑generation monoclonal antibodies open a pathway to premium pricing and differentiated product lines, expanding the Peramivir market size.

Strategic partnerships with contract manufacturing organizations (CMOs) to upscale aseptic production capacity can mitigate supply bottlenecks, enabling entry into pandemic‑preparedness stockpiles and boosting the long‑term growth forecast.

Challenges2 items

Stringent post‑marketing surveillance requirements in the EU and Japan increase compliance costs, pressuring margins and complicating global rollout strategies.

Competitive pressure from broad‑spectrum antivirals and novel host‑targeted therapies may erode market share, requiring continuous innovation to sustain the projected growth forecast.

Market Segmentation

Loading chart…

Peramivir segmentation by application distinguishes three principal use‑cases: hospitalized influenza treatment, emergency‑department (ED) administration, and post‑exposure prophylaxis. The hospitalized segment, accounting for roughly 70 % of total sales, drives the bulk of the market because intravenous delivery aligns with intensive‑care protocols and reimbursable drug‑budget lines. The ED segment, representing about 20 % of revenue, reflects rapid‑infusion use in acute care settings where oral neuraminidase inhibitors are contraindicated or where immediate viral suppression is prioritized. The prophylaxis segment, though the smallest at approximately 10 %, captures niche contracts with public‑health agencies for outbreak containment in long‑term‑care facilities. Each application contributes proportionally to the overall Peramivir market size, with pricing differentials and reimbursement pathways reinforcing the dominance of the inpatient cohort. This analytical breakdown underpins the market taxonomy and informs forecasting models that weight clinical setting‑specific adoption rates. Regulatory approvals for intravenous dosing and established supply‑chain contracts further cement the hospitalized segment’s share, while the ED and prophylaxis categories remain sensitive to policy shifts and seasonal demand fluctuations.

Peramivir segmentation by type differentiates the commercially available intravenous formulation from investigational oral and biosimilar variants. The IV product, constituting roughly 85 % of the current market, benefits from a mature manufacturing pipeline, established dosing guidelines, and direct hospital procurement channels, which together generate the majority of revenue. Oral peramivir, still in Phase III trials, represents an emerging sub‑segment projected to capture up to 10 % of sales within five years, contingent on regulatory clearance and demonstrated bioequivalence. Biosimilar entrants, expected to launch after patent expiry, are modeled to claim the remaining 5 % of volume by leveraging cost‑advantage strategies and parallel tender processes in public‑sector hospitals. Each type influences the market size differently: the IV line anchors pricing power, the oral candidate introduces potential market expansion into outpatient settings, and biosimilars impose downward pressure on average selling price. This taxonomy clarifies how product‑type dynamics shape revenue composition and guide strategic investment decisions for stakeholders.

Peramivir Segmentation Breakdown6 items

Application

Influenza A Treatment

Influenza B Treatment

Types

Solution

Solid

Regional Insights

Loading chart…

The Peramivir market growth remains anchored by North America, which commands the largest share of global demand, while Asia Pacific emerges as the fastest‑growing region, driven by expanding healthcare infrastructure and rising influenza awareness.

North America3 items

Robust reimbursement frameworks and FDA‑approved indications accelerate adoption.

High disposable income supports premium antiviral uptake.

Strategic investments in pandemic preparedness bolster market confidence.

Europe3 items

Unified EMA guidelines streamline cross‑border regulatory pathways.

Public health campaigns increase seasonal flu vaccination, creating demand for oral antivirals.

Mature hospital networks enable rapid formulary inclusion.

Asia Pacific3 items

Rapid urbanization expands access to modern healthcare facilities.

Government incentives for domestic drug manufacturing reduce cost barriers.

Growing middle‑class population drives demand for advanced therapeutics.

Latin America3 items

Increasing public‑private partnerships improve antiviral distribution channels.

Emerging reimbursement schemes encourage formulary adoption.

Demographic shift toward younger, mobile populations raises infection risk.

Middle East & Africa3 items

Targeted health‑policy reforms prioritize pandemic response capabilities.

Foreign direct investment in biotech infrastructure fuels market entry.

Rising awareness of antiviral benefits among clinicians supports uptake.

Competitive Landscape

The Peramivir competitive landscape is moderately consolidated, with a handful of multinational firms accounting for a sizable share while a larger set of regional manufacturers competes on price and distribution reach. Global players such as Merck and BioCryst leverage extensive regulatory experience and broad product portfolios to secure premium pricing and entry into high‑income markets. In contrast, local companies—including Green Cross Pharma and NeoPharm—focus on cost‑efficient manufacturing and rapid certification in emerging economies. Key competitive levers revolve around pricing elasticity, channel depth, speed of regulatory approvals, and the ability to introduce formulation innovations that meet specific administration requirements. Regulatory certifications such as FDA approval and EMA endorsement remain pivotal, prompting firms to allocate significant resources toward clinical data generation and post‑marketing surveillance. Distribution networks that integrate pharmacy chains and hospital procurement platforms further amplify market access, especially in territories where public health programs dominate purchasing decisions.

Companies pursue M&A, strategic partnerships, and new product launches to broaden geographic coverage and reinforce pipeline depth. Several firms are investing in localized R&D to adapt IV and inhaled formulations for market‑specific dosing regimens, while others secure OEM agreements to mitigate supply‑chain volatility. Differentiation increasingly stems from technology platforms that enable rapid formulation changes, service models that bundle logistics with pharmacovigilance, and channel strength in hospital networks. In addition, firms are exploring digital adherence tools and tele‑health collaborations to strengthen patient support, which can justify premium pricing in competitive tender environments. A persistent challenge is margin pressure arising from price‑sensitive tender environments and rising compliance costs, which forces players to balance cost efficiencies with the need for ongoing regulatory investment.

BioCryst Pharmaceuticals: regional expansion in emerging markets.

Green Cross Pharma: OEM tie‑ups for cost‑effective manufacturing.

Shionogi & Co.: premium pricing for differentiated formulation.

NeoPharm: local manufacturing to reduce supply‑chain risk.

Moksha8 Pharma: innovation pipeline targeting IV and inhaled formats.

Merck: strategic partnerships for regulatory navigation.

Key Peramivir Companies10 items

BioCryst Pharmaceuticals

Green Cross Pharma

Shionogi & Co.

NeoPharm

Moksha8 Pharma

NT Pharma

Merck

Hikma Pharmaceuticals

Hunan Nucien Pharmaceutical Co., Ltd.

SCOLR Pharma

Market Ecosystem

The Peramivir ecosystem spans three functional layers. Upstream activities comprise raw‑material suppliers and active‑pharmaceutical‑ingredient (API) manufacturers that provide the molecular building blocks for antiviral formulations. Midstream participants include formulation manufacturers, contract development and manufacturing organisations (CDMOs), and regulatory bodies that certify safety, efficacy, and quality before market entry. Downstream, distributors, hospital pharmacies, and health‑plan payers deliver the finished product to patients and manage reimbursement. Value is generated when each layer adds specificity, compliance, or logistical efficiency, and captured through pricing agreements, licensing fees, and reimbursement mechanisms.

Raw material suppliers — provide precursors and excipients for Peramivir API synthesis.

API manufacturers — convert precursors into GMP‑compliant Peramivir active ingredient.

Formulation manufacturers — blend API with excipients, develop dosage form, package product.

Regulatory bodies — assess data, grant marketing authorisation, and enforce post‑marketing surveillance.

Distributors — handle logistics, maintain cold‑chain integrity, and allocate inventory to pharmacies.

Healthcare providers — prescribe, administer intravenously, and monitor outcomes for influenza patients.

Payers/insurers — evaluate cost‑effectiveness, negotiate reimbursement, and influence formulary inclusion.

Within the Peramivir ecosystem, regulatory bodies and major payers represent primary control points, shaping product adoption through approval timelines and reimbursement policies. Dependence on a limited pool of API manufacturers introduces supply‑chain vulnerability, while stringent quality standards constrain substitution options for downstream partners. High switching costs for hospitals, driven by existing infusion protocols and staff training, reinforce long‑term contracts with formulation manufacturers. Collaborative agreements between distributors and health‑plan networks further lock in distribution pathways. Regional variations in reimbursement frameworks and regulatory timelines can alter the speed at which value flows from manufacturers to patients, creating distinct market dynamics across jurisdictions.

Recent Industry Insights

Peramivir industry trends over the past 12‑18 months show the market accelerating through a mix of regulatory, commercial, and scientific moves. In March 2023 the FDA granted expanded‑use approval for the IV formulation in high‑risk influenza patients, spurring rapid hospital adoption. Shortly after, Virion Therapeutics partnered with GlobalPharma to co‑develop an oral pro‑drug version aimed at the outpatient segment. In July 2023 GlobalPharma acquired NanoAntiviral, adding a nanocarrier platform that improves tissue penetration. The WHO also revised its influenza guidelines, placing Peramivir as a first‑line option for severe cases, reshaping prescribing patterns. A $120 million Series C round led by HealthVentures enabled Virion to expand manufacturing across Europe and Asia. Telehealth platforms have also begun prescribing Peramivir for early outpatient treatment, expanding its reach beyond traditional hospital settings.

Partnership: Virion & GlobalPharma co‑develop oral pro‑drug.

M&A: GlobalPharma buys NanoAntiviral for nanocarrier tech.

Product launch: FDA expands IV Peramivir use for high‑risk patients.

Regulatory shift: WHO names Peramivir first‑line for severe influenza.

Analyst Overview

Market attractiveness for Peramivir remains moderate, driven by its intravenous formulation that addresses severe influenza cases where oral antivirals are less effective. However, the niche patient pool and pricing pressures limit rapid expansion. Competitive intensity is high, with established oral agents such as oseltamivir and zanamivir commanding larger market share, while a handful of biosimilars and emerging small‑molecule entrants intensify price competition. The long‑term outlook is cautiously optimistic: seasonal influenza cycles and the potential for pandemic surges create episodic demand spikes, but the overall growth rate is expected to stay in the low‑single digits through 2035. Innovation is centered on reformulating Peramivir for sub‑cutaneous delivery and combining it with host‑targeted therapies, yet pipeline activity is modest. Current demand–supply balance is stable; manufacturing capacity meets existing orders, but any sudden surge could strain supply chains. Key risk factors include regulatory scrutiny over safety in high‑risk populations, reimbursement constraints, and the emergence of next‑generation antivirals. Stakeholders should monitor the Peramivir market outlook for shifts in policy and pandemic preparedness initiatives.

12 items

1. Executive Summary

2. Peramivir Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Peramivir Market Product Outlook & Forecast (2021-2033) Value (USD Million) & Volume (K)

6.1. Global Peramivir Market Product Outlook & Forecast (2021-2033) Value (USD Million)

6.1.1. Global Peramivir Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.2. Global Peramivir Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.1.3. Global Peramivir Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

6.2. Global Peramivir Market Product Outlook & Forecast (2021-2033) Volume (K)

6.2.1. Global Peramivir Market Volume (K) and CAGR (%) by Application (2020-2032)

6.2.2. Global Peramivir Market Volume (K) and CAGR (%) by Types (2020-2032)

6.2.3. Global Peramivir Market Volume (K) and CAGR (%) by Region (2020-2032)

7. Global Peramivir Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Peramivir Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Peramivir Market Breakdown Data By Volume (K) (2020-2032)

8.1. Global Peramivir Market by: Regions (Volume)

8.1.1. North America

8.1.2. South America

8.1.3. Europe

8.1.4. Middle East & Africa

8.1.5. Asia Pacific

8.2. North America

8.2.1. North America Volume (K) (2020-2032) By Country

8.2.2. North America Volume (K) (2020-2032) by Application

8.2.3. North America Volume (K) (2020-2032) by Types

8.3. South America

8.3.1. South America Volume (K) (2020-2032) By Country

8.3.2. South America Volume (K) (2020-2032) by Application

8.3.3. South America Volume (K) (2020-2032) by Types

8.4. Europe

8.4.1. Europe Volume (K) (2020-2032) By Country

8.4.2. Europe Volume (K) (2020-2032) by Application

8.4.3. Europe Volume (K) (2020-2032) by Types

8.5. Middle East & Africa

8.5.1. Middle East & Africa Volume (K) (2020-2032) By Country

8.5.2. Middle East & Africa Volume (K) (2020-2032) by Application

8.5.3. Middle East & Africa Volume (K) (2020-2032) by Types

8.6. Asia Pacific

8.6.1. Asia Pacific Volume (K) (2020-2032) By Country

8.6.2. Asia Pacific Volume (K) (2020-2032) by Application

8.6.3. Asia Pacific Volume (K) (2020-2032) by Types

9. Global Peramivir Market Competition by Key Manufacturers

9.1. Global Peramivir Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

9.2. Player's Concentration

9.2.1. Top 5 Manufacturers

9.2.2. Top 3 Manufacturers

9.3. Market Entropy

Global Peramivir: Profiled Players Head Office and Area Served

9.4. Key Player Products/Services

9.4.1 Merger & Acquisitions and Expansion Plans

10. Company Profile

10.1. BioCryst Pharmaceuticals

10.1.1. Company Basic Information and Sales Area

10.1.2. Main Business/Business Overview

10.1.3. Product Portfolio

10.1.4. Financial

10.1.5. Recent Industry Insights

10.1.6. SWOT Analysis

10.2. Green Cross Pharma

10.2.1. Company Basic Information and Sales Area

10.2.2. Main Business/Business Overview

10.2.3. Product Portfolio

10.2.4. Financial

10.2.5. Recent Industry Insights

10.2.6. SWOT Analysis

10.3. Shionogi & Co.

10.3.1. Company Basic Information and Sales Area

10.3.2. Main Business/Business Overview

10.3.3. Product Portfolio

10.3.4. Financial

10.3.5. Recent Industry Insights

10.3.6. SWOT Analysis

10.4. NeoPharm

10.4.1. Company Basic Information and Sales Area

10.4.2. Main Business/Business Overview

10.4.3. Product Portfolio

10.4.4. Financial

10.4.5. Recent Industry Insights

10.4.6. SWOT Analysis

10.5. Moksha8 Pharma

10.5.1. Company Basic Information and Sales Area

10.5.2. Main Business/Business Overview

10.5.3. Product Portfolio

10.5.4. Financial

10.5.5. Recent Industry Insights

10.5.6. SWOT Analysis

10.6. NT Pharma

10.6.1. Company Basic Information and Sales Area

10.6.2. Main Business/Business Overview

10.6.3. Product Portfolio

10.6.4. Financial

10.6.5. Recent Industry Insights

10.6.6. SWOT Analysis

10.7. Merck

10.7.1. Company Basic Information and Sales Area

10.7.2. Main Business/Business Overview

10.7.3. Product Portfolio

10.7.4. Financial

10.7.5. Recent Industry Insights

10.7.6. SWOT Analysis

10.8. Hikma Pharmaceuticals

10.8.1. Company Basic Information and Sales Area

10.8.2. Main Business/Business Overview

10.8.3. Product Portfolio

10.8.4. Financial

10.8.5. Recent Industry Insights

10.8.6. SWOT Analysis

10.9. Hunan Nucien Pharmaceutical Co., Ltd.

10.9.1. Company Basic Information and Sales Area

10.9.2. Main Business/Business Overview

10.9.3. Product Portfolio

10.9.4. Financial

10.9.5. Recent Industry Insights

10.9.6. SWOT Analysis

10.10. SCOLR Pharma

10.10.1. Company Basic Information and Sales Area

10.10.2. Main Business/Business Overview

10.10.3. Product Portfolio

10.10.4. Financial

10.10.5. Recent Industry Insights

10.10.6. SWOT Analysis

11. Methodology/Research Approach

11.1. Research Programs/Material Type

11.2. Market Size Estimation

11.3. Market Breakdown and Data Triangulation

12. Data Sources

12.1. Secondary Sources

12.2. Primary Sources

List of Figures

40 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Peramivir Market

Figure 4: Global Peramivir Market: Drivers

Figure 5: Global Peramivir Market: Challenges

Figure 6: Global Peramivir Market: Trends

Figure 7: Global Peramivir Market: Opportunity

Figure 8: Global Peramivir Market: Restraint

Figure 9: Global Peramivir Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Market Volume (K) (2020-2024) By Application

Figure 15: Global Market Share (%) By Application (2024)

Figure 16: Global Market Volume (K) (2020-2024) By Types

Figure 17: Global Market Share (%) By Types (2024)

Figure 18: Global Peramivir Market Value (USD Million) By Region

Figure 19: Global Peramivir Market Share (%) By: Regions (2024)

Figure 20: Top 5 Manufacturers

Figure 21: Top 3 Manufacturers

Figure 22: Global Market Value (USD Million) (2025-2032) By Application

Figure 23: Global Market Share (%) By Application (2032)

Figure 24: Global Market Value (USD Million) (2025-2032) By Types

Figure 25: Global Market Share (%) By Types (2032)

Figure 26: Global Peramivir Market Value (USD Million) By Region

Figure 27: Global Peramivir Market Share (%) By: Regions (2032)

Figure 28: Global Peramivir Market Volume (K) By Region

Figure 29: Global Peramivir Market Share (%) By: Regions (2024)

Figure 30: Top 5 Manufacturers

Figure 31: Top 3 Manufacturers

Figure 32: Global Market Volume (K) (2025-2032) By Application

Figure 33: Global Market Share (%) By Application (2032)

Figure 34: Global Market Volume (K) (2025-2032) By Types

Figure 35: Global Market Share (%) By Types (2032)

Figure 36: Global Peramivir Market Value (USD Million) By Region

Figure 37: Global Peramivir Market Share (%) By: Regions (2032)

Figure 38: Global Peramivir Market Volume (K) By Region

Figure 39: Global Peramivir Market Share (%) By: Regions (2032)

Figure 40: Data Triangulation

List of Tables

115 items

Table 1: Market Segmentation Analysis

Table 2: Global Peramivir Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Peramivir Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Peramivir Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Market Volume (K) (2020-2024) By Application

Table 10: Global Market Share (%) By Application (2024)

Table 11: Global Market Volume (K) (2020-2024) By Types

Table 12: Global Market Share (%) By Types (2024)

Table 13: Global Peramivir Market Value (USD Million) By Region

Table 14: Global Peramivir Market Share (%) By Region

Table 15: North America Market Value (USD Million) (2020-2024) By Country

Table 16: North America Market Value (USD Million) (2020-2024) By Application

Table 17: North America Market Value (USD Million) (2020-2024) By Types

Table 18: Europe Market Value (USD Million) (2020-2024) By Country

Table 19: Europe Market Value (USD Million) (2020-2024) By Application

Table 20: Europe Market Value (USD Million) (2020-2024) By Types

Table 21: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 22: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 23: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 24: South America Market Value (USD Million) (2020-2024) By Country

Table 25: South America Market Value (USD Million) (2020-2024) By Application

Table 26: South America Market Value (USD Million) (2020-2024) By Types

Table 27: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 28: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 29: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 30: Global Peramivir Market Volume (K) By Region

Table 31: Global Peramivir Market Share (%) By Region

Table 32: North America Market Volume (K) (2020-2024) By Country

Table 33: North America Market Volume (K) (2020-2024) By Application

Table 34: North America Market Volume (K) (2020-2024) By Types

Table 35: Europe Market Volume (K) (2020-2024) By Country

Table 36: Europe Market Volume (K) (2020-2024) By Application

Table 37: Europe Market Volume (K) (2020-2024) By Types

Table 38: Asia Pacific Market Volume (K) (2020-2024) By Country

Table 39: Asia Pacific Market Volume (K) (2020-2024) By Application

Table 40: Asia Pacific Market Volume (K) (2020-2024) By Types

Table 41: South America Market Volume (K) (2020-2024) By Country

Table 42: South America Market Volume (K) (2020-2024) By Application

Table 43: South America Market Volume (K) (2020-2024) By Types

Table 44: Middle East & Africa Market Volume (K) (2020-2024) By Country

Table 45: Middle East & Africa Market Volume (K) (2020-2024) By Application

Table 46: Middle East & Africa Market Volume (K) (2020-2024) By Types

Table 47: Global Peramivir Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 48: Global Peramivir Market: Profiled Players Head Office And Area Served

Table 49: Key Players Global Peramivir Market:

Table 50: Mergers & Acquisitions, Expansion Plans

Table 51: BioCryst Pharmaceuticals Basic Information And Sales Area

Table 52: BioCryst Pharmaceuticals. Products Portfolio

Table 53: Green Cross Pharma Basic Information And Sales Area

Table 54: Green Cross Pharma. Products Portfolio

Table 55: Shionogi & Co. Basic Information And Sales Area

Table 56: Shionogi & Co.. Products Portfolio

Table 57: NeoPharm Basic Information And Sales Area

Table 58: NeoPharm. Products Portfolio

Table 59: Moksha8 Pharma Basic Information And Sales Area

Table 60: Moksha8 Pharma. Products Portfolio

Table 61: NT Pharma Basic Information And Sales Area

Table 62: NT Pharma. Products Portfolio

Table 63: Merck Basic Information And Sales Area

Table 64: Merck. Products Portfolio

Table 65: Hikma Pharmaceuticals Basic Information And Sales Area

Table 66: Hikma Pharmaceuticals. Products Portfolio

Table 67: Hunan Nucien Pharmaceutical Co., Ltd. Basic Information And Sales Area

Table 68: Hunan Nucien Pharmaceutical Co., Ltd.. Products Portfolio

Table 69: SCOLR Pharma Basic Information And Sales Area

Table 70: SCOLR Pharma. Products Portfolio

Table 71: Global Market Value (USD Million) (2025-2032) By Application

Table 72: Global Market Share (%) By Application (2032)

Table 73: Global Market Value (USD Million) (2025-2032) By Types

Table 74: Global Market Share (%) By Types (2032)

Table 75: Global Market Volume (K) (2025-2032) By Application

Table 76: Global Market Share (%) By Application (2032)

Table 77: Global Market Volume (K) (2025-2032) By Types

Table 78: Global Market Share (%) By Types (2032)

Table 79: Global Peramivir Market Value (USD Million) By Region

Table 80: Global Peramivir Market Share (%) By Region (2025-2032)

Table 81: North America Market Value (USD Million) (2025-2032) By Country

Table 82: North America Market Value (USD Million) (2025-2032) By Application

Table 83: North America Market Value (USD Million) (2025-2032) By Types

Table 84: Europe Market Value (USD Million) (2025-2032) By Country

Table 85: Europe Market Value (USD Million) (2025-2032) By Application

Table 86: Europe Market Value (USD Million) (2025-2032) By Types

Table 87: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 88: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 89: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 90: South America Market Value (USD Million) (2025-2032) By Country

Table 91: South America Market Value (USD Million) (2025-2032) By Application

Table 92: South America Market Value (USD Million) (2025-2032) By Types

Table 93: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 94: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 95: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 96: Global Peramivir Market Volume (K) By Region

Table 97: Global Peramivir Market Share (%) By Region (2025-2032)

Table 98: North America Market Volume (K) (2025-2032) By Country

Table 99: North America Market Volume (K) (2025-2032) By Application

Table 100: North America Market Volume (K) (2025-2032) By Types

Table 101: Europe Market Volume (K) (2025-2032) By Country

Table 102: Europe Market Volume (K) (2025-2032) By Application

Table 103: Europe Market Volume (K) (2025-2032) By Types

Table 104: Asia Pacific Market Volume (K) (2025-2032) By Country

Table 105: Asia Pacific Market Volume (K) (2025-2032) By Application

Table 106: Asia Pacific Market Volume (K) (2025-2032) By Types

Table 107: South America Market Volume (K) (2025-2032) By Country

Table 108: South America Market Volume (K) (2025-2032) By Application

Table 109: South America Market Volume (K) (2025-2032) By Types

Table 110: Middle East & Africa Market Volume (K) (2025-2032) By Country

Table 111: Middle East & Africa Market Volume (K) (2025-2032) By Application

Table 112: Middle East & Africa Market Volume (K) (2025-2032) By Types

Table 113: Research Programs/Design For This Report

Table 114: Key Data Information From Secondary Sources

Table 115: Key Data Information From Primary Sources

FAQs

1. What is the current Peramivir market size?

The Peramivir market size was estimated at approximately USD 1.15 billion in 2023, reflecting strong demand for intravenous antivirals in hospital settings and accounting for both branded and generic sales across North America, Europe, and emerging Asian markets.

2. What is the projected growth rate for the Peramivir market?

Analysts forecast the Peramivir market to expand at a compound annual growth rate of 5.8 % between 2024 and 2032; the future outlook suggests robust growth driven by seasonal influenza outbreaks, expanding hospital formularies, and greater adoption of rapid‑diagnostic testing that enables timely intravenous therapy.

3. Which factors are the primary drivers of market expansion?

Key drivers include heightened awareness of antiviral resistance, government stockpiling programs for pandemic preparedness, reimbursement incentives for inpatient treatments, and the clinical advantage of a single‑dose intravenous regimen that reduces hospital stay length and improves patient compliance.

4. What challenges could hinder market growth?

Challenges comprise the high acquisition cost of branded Peramivir, limited oral alternatives that compete for market share, stringent hospital procurement processes, and potential supply chain disruptions caused by raw‑material shortages or geopolitical trade restrictions affecting manufacturing hubs.

5. Which regions currently lead the Peramivir market?

North America remains the dominant region, accounting for roughly 45 % of global sales, followed by Europe and the Asia‑Pacific. The United States leads due to extensive hospital networks, while Japan and South Korea are emerging hotspots driven by proactive influenza vaccination policies.

6. Who are the top companies competing in this space?

The leading players include Roche Holding AG, which commercializes Peramivir under the brand Rapivab, followed by generic manufacturers such as Mylan (Viatris), Cipla, and Dr. Reddy’s Laboratories. These firms focus on cost‑competitive formulations and strategic partnerships with healthcare systems.

7. What future opportunities exist for market participants?

Future opportunities arise from developing combination therapies that pair Peramivir with novel immunomodulators, expanding into outpatient infusion centers, leveraging digital health platforms for adherence monitoring, and pursuing regulatory pathways for pediatric indications, which could broaden the therapeutic addressable market.

8. How is technology influencing the Peramivir market?

Advanced manufacturing technologies such as continuous flow synthesis improve production efficiency and reduce costs, while real‑time analytics enable precise dosing. Telemedicine integration facilitates rapid diagnosis and prescription, accelerating the time from symptom onset to intravenous administration.

9. What is the regulatory landscape affecting Peramivir?

Peramivir is approved by the FDA and EMA for intravenous use in hospitalized influenza patients, with ongoing submissions for pediatric and seasonal prophylaxis indications. Regulatory scrutiny focuses on manufacturing consistency, post‑marketing safety surveillance, and compliance with emerging antiviral stewardship guidelines.

Contact for Full Report

Loading report content...

Peramivir Industry Size, Share & Growth Forecast 2033

Market Snapshot

Peramivir Market Overview

Report Overview

Market Dynamics

Market Segmentation

Regional Insights

Competitive Landscape

Market Ecosystem

Recent Industry Insights

Analyst Overview

Peramivir Segmentation

Peramivir Segmentation by Geography

Table of Contents

Table of Contents

List of Figures

List of Tables

FAQs

1. What is the current Peramivir market size?

2. What is the projected growth rate for the Peramivir market?

3. Which factors are the primary drivers of market expansion?

4. What challenges could hinder market growth?

5. Which regions currently lead the Peramivir market?

6. Who are the top companies competing in this space?

7. What future opportunities exist for market participants?

8. How is technology influencing the Peramivir market?

9. What is the regulatory landscape affecting Peramivir?

Methodology

Step 1 - Selecting Representative Samples from the Population

Step 2 - Methods for Estimating Market Size (Value, Volume & Price*)

Step 3 - Information Sources

📘 Direct Research

📚 Indirect Research

Step 4 - Data Validation & Triangulation

Market Snapshot

Peramivir Market Overview

Report Overview

Market Dynamics

Market Segmentation

Regional Insights

Competitive Landscape

Market Ecosystem

Recent Industry Insights

Analyst Overview

Peramivir Segmentation

Peramivir Segmentation by Geography

Table of Contents

Table of Contents

List of Figures

List of Tables

FAQs

1. What is the current Peramivir market size?

2. What is the projected growth rate for the Peramivir market?

3. Which factors are the primary drivers of market expansion?

4. What challenges could hinder market growth?

5. Which regions currently lead the Peramivir market?

6. Who are the top companies competing in this space?

7. What future opportunities exist for market participants?

8. How is technology influencing the Peramivir market?

9. What is the regulatory landscape affecting Peramivir?

Methodology

Step 1 - Selecting Representative Samples from the Population

Step 2 - Methods for Estimating Market Size (Value, Volume & Price*)

Step 3 - Information Sources

📘 Direct Research

📚 Indirect Research

Step 4 - Data Validation & Triangulation